340
Views
13
CrossRef citations to date
0
Altmetric
CLINICAL STUDY

Increased Endothelin: Nitric Oxide Ratio Is Associated with Erythropoietin-Induced Hypertension in Hemodialysis Patients

, , , , , , & show all
Pages 569-578 | Published online: 07 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Emine Meltem Onal, Alan Alper Sag, Oguzhan Sal, Aslihan Yerlikaya, Baris Afsar & Mehmet Kanbay. (2017) Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension. Clinical and Experimental Hypertension 39:3, pages 197-209.
Read now

Articles from other publishers (12)

Satoshi Umemura, Hisatomi Arima, Shuji Arima, Kei Asayama, Yasuaki Dohi, Yoshitaka Hirooka, Takeshi Horio, Satoshi Hoshide, Shunya Ikeda, Toshihiko Ishimitsu, Masaaki Ito, Sadayoshi Ito, Yoshio Iwashima, Hisashi Kai, Kei Kamide, Yoshihiko Kanno, Naoki Kashihara, Yuhei Kawano, Toru Kikuchi, Kazuo Kitamura, Takanari Kitazono, Katsuhiko Kohara, Masataka Kudo, Hiroo Kumagai, Kiyoshi Matsumura, Hideo Matsuura, Katsuyuki Miura, Masashi Mukoyama, Satoko Nakamura, Takayoshi Ohkubo, Yusuke Ohya, Takafumi Okura, Hiromi Rakugi, Shigeyuki Saitoh, Hirotaka Shibata, Tatsuo Shimosawa, Hiromichi Suzuki, Shori Takahashi, Kouichi Tamura, Hirofumi Tomiyama, Takuya Tsuchihashi, Shinichiro Ueda, Yoshinari Uehara, Hidenori Urata & Nobuhito Hirawa. (2019) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research 42:9, pages 1235-1481.
Crossref
Nagalakshmi Nagarajan & Diana Jalal. (2019) Resistant Hypertension: Diagnosis and Management. Advances in Chronic Kidney Disease 26:2, pages 99-109.
Crossref
Naoki Oshima, Hiroshi Onimaru, Akira Yamagata, Seigo Itoh, Hidehito Matsubara, Toshihiko Imakiire, Yasuhiro Nishida & Hiroo Kumagai. (2018) Erythropoietin, a putative neurotransmitter during hypoxia, is produced in RVLM neurons and activates them in neonatal Wistar rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 314:5, pages R700-R708.
Crossref
Alon Grossman, Franz H. Messerli & Ehud Grossman. (2015) Drug induced hypertension – An unappreciated cause of secondary hypertension. European Journal of Pharmacology 763, pages 15-22.
Crossref
. (2014) Chapter 13. Secondary hypertension. Hypertension Research 37:4, pages 349-361.
Crossref
Tlili BarhoumiIsabelle JallatAlain BerthelotPascal Laurant. (2011) Human recombinant erythropoietin alters the flow-dependent vasodilatation of in vitro perfused rat mesenteric arteries with unbalanced endothelial endothelin-1 / nitric oxide ratio. Canadian Journal of Physiology and Pharmacology 89:6, pages 435-443.
Crossref
Won Seok Yang, Jai Won Chang, Nam Jeong Han & Su-Kil Park. (2011) Darbepoetin alfa suppresses tumor necrosis factor-α-induced endothelin-1 production through antioxidant action in human aortic endothelial cells: Role of sialic acid residues. Free Radical Biology and Medicine 50:10, pages 1242-1251.
Crossref
E.P. Cohen & J.-M. Krzesinski. (2007) La physiopathologie de l’hypertension artérielle en dialyse chronique. Néphrologie & Thérapeutique 3, pages S150-S155.
Crossref
Mary S. LeeJohn S. LeeJong Y. Lee. (2007) Prevention of Erythropoietin-Associated Hypertension. Hypertension 50:2, pages 439-445.
Crossref
Merih Bayram, Orhan Bayram, M. Yasemin Karadeniz Bilgili, Osman Caglayan & Mustafa N. Ilhan. (2013) Evaluation of hormone replacement therapy which may have an adrenomedullin-mediated protective effect on cardiovascular disorders. Aging Clinical and Experimental Research 19:3, pages 224-227.
Crossref
Mehmet Kanbay, Ali Akcay, Tuncay Delibasi, Burak Uz, Arif Kaya, Cemile Koca, Faruk Turgut, Nuket Bavbek, Ebru Uz, Murat Duranay & Ramazan Yigitoglu. (2007) Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Advances in Therapy 24:2, pages 346-352.
Crossref
Ehud Grossman & Franz H. Messerli. 2007. Comprehensive Hypertension. Comprehensive Hypertension 883 893 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.